JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

Kodu・Aktsiate loetelu・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Suletud

SektorTervishoid

511.87 -1.1

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

504.99

Max

521.24

Põhinäitajad
By Trading Economics
Sissetulek	56M -59M
Müük	34M 321M
Kasumimarginaal	-18.243
Töötajad	915
EBITDA	56M -50M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+28.32% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. mai 2026

Turustatistika
By TradingEconomics
Turukapital	1.5B 12B
Eelmine avamishind	512.97
Eelmine sulgemishind	511.87

Uudiste sentiment

By Acuity

92%

13 / 348 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

263.2 / 277.1 Toetus ja vastupanu

Madrigal Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. apr 2026, 19:19 UTC

Omandamised, ülevõtmised, äriostud

Intertek Group Rejects EQT's Revised Offer

24. apr 2026, 23:37 UTC

Omandamised, ülevõtmised, äriostud

Scoring the Cook Era -- Barrons.com

24. apr 2026, 20:51 UTC

Omandamised, ülevõtmised, äriostud

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24. apr 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Financial Services Roundup: Market Talk

24. apr 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

24. apr 2026, 20:39 UTC

Omandamised, ülevõtmised, äriostud

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24. apr 2026, 20:09 UTC

Tulu

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24. apr 2026, 19:48 UTC

Market Talk

Uudisväärsed sündmused

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24. apr 2026, 19:25 UTC

Omandamised, ülevõtmised, äriostud

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24. apr 2026, 19:25 UTC

Omandamised, ülevõtmised, äriostud

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24. apr 2026, 19:22 UTC

Tulu

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24. apr 2026, 19:06 UTC

Tulu

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24. apr 2026, 19:05 UTC

Market Talk

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24. apr 2026, 18:30 UTC

Omandamised, ülevõtmised, äriostud

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24. apr 2026, 18:28 UTC

Omandamised, ülevõtmised, äriostud

Intertek Rejects Revised EQT Offer

24. apr 2026, 18:12 UTC

Market Talk

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24. apr 2026, 18:06 UTC

Market Talk

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24. apr 2026, 17:42 UTC

Tulu

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24. apr 2026, 17:28 UTC

Tulu

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

24. apr 2026, 17:28 UTC

Market Talk

Crypto Fear and Greed Index Slides Back to Neutral -- Market Talk

24. apr 2026, 17:12 UTC

Market Talk

Global Equities Roundup: Market Talk

24. apr 2026, 17:11 UTC

Market Talk

Apple Seen Gaining Market Share Despite Memory Crunch -- Market Talk

24. apr 2026, 17:09 UTC

Market Talk

Tulu

Intel Seen With Stronger Long-Term Earnings Power -- Market Talk

24. apr 2026, 17:09 UTC

Omandamised, ülevõtmised, äriostud

Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24. apr 2026, 17:06 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Correction to Advanced Micro Devices Stock Gets Upgraded to Buy. Why It's the Big Winner of Intel Earnings. -- Barrons.com

24. apr 2026, 16:51 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Two Big Loan Defaults Add to Pain in Private-Credit Funds -- WSJ

24. apr 2026, 16:20 UTC

Market Talk

Tulu

Tech, Media & Telecom Roundup: Market Talk

24. apr 2026, 16:20 UTC

Market Talk

Uudisväärsed sündmused

Financial Services Roundup: Market Talk

24. apr 2026, 16:20 UTC

Market Talk

Tulu

Auto & Transport Roundup: Market Talk

24. apr 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Madrigal Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

28.32% tõus

12 kuu keskmine prognoos

Keskmine 665.67 USD 28.32%

Kõrge 964 USD

Madal 529 USD

Põhineb 7 Wall Streeti analüütiku instrumendi Madrigal Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

7 ratings

Osta

Hoia

Müü

Põhineb 7 analüütiku instrumendi Madrigal Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

263.2 / 277.1Toetus ja vastupanu

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

13 / 348 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.